Vamstar

The logic behind Section 232 tariffs is simple on paper: make imports more expensive, and companies will build the alternative at home. It worked, more or less, as the stated goal for steel and aluminum in 2018. The Trump administration is betting the sam

The MDR transition gives eligible devices until 2027 or 2028 to move into the new regulatory framework. For manufacturers, the additional runway is already shaping certification priorities, portfolio decisions and future tender opportunities. For MedTech

What commercial-execution AI actually has to do in tendering and contracting The market is counting agents. Commercial leaders should be counting qualified opportunities, compliant submissions, win rate and margin. Roughly 40% of medicines in Europe are n

Why cross-referencing and product matching have become the hidden capability behind faster RFP responses, tighter margin discipline, and lower contract leakage in US healthcare contracting In US healthcare contracting, the hardest part of responding to an

In December, the argument was that MedTech's new competitive surface area is assurance: the ability to operationalise trust at scale across procurement, regulation, cybersecurity, data governance, and AI governance. Buyers were institutionalising risk con

A dollar of procurement savings delivers the same profit improvement as roughly $6 of new revenue. That arithmetic is forcing a rethink of where MedTech companies focus their commercial energy. For most of the past decade, the working assumption in medica

AI in tender management has moved fast. Across the industry, vendors are building tools that can read a tender document, answer a question, draft a paragraph on demand. The progress is real and the direction is right. But as the technology matures, an imp

Continuous discovery. Faster decisions. Stronger margins. The next phase of MedTech commercial advantage starts inside agreements you already own. The largest unclaimed margin pool in MedTech is not waiting in the next tender. It is already sitting inside

Margins are tightening. Tenders are more competitive. Teams are being asked to deliver more with fragmented data and limited bandwidth. AI is no longer experimental - it is becoming a practical commercial lever for teams working across tendering, pricing,

Ahead of The MedTech Forum 2026 in Stockholm, Vamstar explores why the next phase of MedTech growth will depend not only on innovation, but on the ability to execute across tenders, pricing, market access, contracts and evidence management. In Stockholm,